Strides Pharma Science Ltd's Q3FY25 Quarter Results
- 31 Jan 2025
Result Summary
- Strides Pharma Science Ltd reported a 5.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 10.8%.
- Its expenses for the quarter were down by 4.9% QoQ and up 7.1% YoY.
- The net profit decreased 3.9% QoQ and increased 66.6% YoY.
- The earnings per share (EPS) of Strides Pharma Science Ltd stood at 9.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1159.28 | 1229.52 | 1046.42 | -5.7% | 10.8% |
Total Expenses | 1043.96 | 1097.97 | 974.37 | -4.9% | 7.1% |
Profit Before Tax | 112.89 | 127.67 | 61.99 | -11.6% | 82.1% |
Tax | 23.80 | 21.20 | 10.10 | 12.3% | 135.6% |
Profit After Tax | 90.04 | 93.66 | 54.06 | -3.9% | 66.6% |
Earnings Per Share | 9.60 | 10.10 | 5.40 | -5.0% | 77.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Strides Pharma Science Ltd is a pharmaceutical company primarily engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates in the pharmaceutical industry, focusing on both generic and branded products across various therapeutic segments. Strides Pharma has a global presence with operations in several countries, enhancing its reach and market penetration. The company's product portfolio includes tablets, capsules, soft gels, and injectables, catering to diverse medical needs. While the company is known for its extensive range of pharmaceutical offerings, specific recent major developments in the company are not available based on the provided information.
Revenue
During the third quarter of the fiscal year 2025 (Q3FY25), Strides Pharma Science Ltd reported a total income of ₹1159.28 crores. This marked a decrease of 5.7% from the previous quarter (Q2FY25), where the total income was ₹1229.52 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY24), there was a notable increase of 10.8% from ₹1046.42 crores. This year-over-year growth suggests an upward trajectory in the company's revenue generation capabilities over the past year, despite the sequential dip observed from the preceding quarter.
Profitability
For Q3FY25, Strides Pharma Science Ltd recorded a profit before tax of ₹112.89 crores, showing a quarter-over-quarter decline of 11.6% from Q2FY25, which stood at ₹127.67 crores. However, there was a significant year-over-year increase of 82.1% compared to Q3FY24, where the profit before tax was ₹61.99 crores. The company's profit after tax for Q3FY25 was ₹90.04 crores, reflecting a slight decrease of 3.9% from ₹93.66 crores in the previous quarter, yet demonstrating a substantial year-over-year growth of 66.6% from ₹54.06 crores. The tax expense for Q3FY25 was ₹23.80 crores, up 12.3% quarter-over-quarter and 135.6% year-over-year. Earnings per share for Q3FY25 stood at ₹9.60, which decreased by 5.0% from the previous quarter but increased by 77.8% from the same quarter in the previous year.
Operating Metrics
Total expenses for Strides Pharma Science Ltd in Q3FY25 amounted to ₹1043.96 crores, down 4.9% from the previous quarter's ₹1097.97 crores. Year-over-year, total expenses increased by 7.1% from ₹974.37 crores in Q3FY24. This change in expenses is crucial for understanding the company's operational efficiency over the quarters. The quarter-over-quarter and year-over-year changes in both revenue and expenses indicate shifts in the company's operational dynamics. The financial data reflects the company's ability to manage its expenses while navigating revenue fluctuations. The company's financial performance during this period is reflected through these operating metrics, providing insight into its operational health and financial management.
